[Current perspectives in the management of non-small cell lung cancer].
Unfortunately, unlike small cell lung cancer, clinical trials of chemotherapy for the treatment of non-small cell lung cancer (NSCLC) have not consistently demonstrated a clinical benefit. However, recent studies have indicated some progress in the development of drug combinations using several active antineoplastic agents with no overlapping toxicity, and, in recent years, clinical trials of combination chemotherapy with such agents as VDS and CDDP have consistently produced response rates of 40 approximately 50%. In this review, we are focusing on the details of updated treatment schedules of combination chemotherapy against NSCLC.
J
J
Fujita
N
N
Saijo
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine
D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin; D014751:Vindesine; D005472:Fluorouracil